EC Number   |
Application |
Reference |
|---|
   2.7.1.137 | drug development |
reduction of PI3K/PKCdelta activity represents a therapeutic target to downregulate adhesion molecule L1, CHL1, expression and thus benefit axonal regeneration after spinal cord injury |
-, 708599 |
| 2.7.1.137 | drug development |
the enzyme is a potential target for drug development, e.g. in cancer therapy, analysis of inhibitory potential of LY294002 inhibotr analogues |
661328 |
| 2.7.1.137 | drug development |
the enzyme is a target for drug design in cancer therapy. Combined targeting of PI3K and mTOR presents an opportunity for robust and synergistic anticancer efficacy |
709478 |
| 2.7.1.137 | drug development |
the PI3K/Akt signaling pathway is a therapeutic target in treatment of medulloblastoma disease, a primitive neuroectodermal tumor, and the most common malignant pediatric brain tumor |
707991 |
| 2.7.1.137 | drug development |
the regulatory subunit p55PIK of PI3K is a trget for inhibitor development in cancer therapy |
709906 |
| 2.7.1.137 | medicine |
dual inhibition of the mTORC1 complex and the IGF-1/IGF-1R/PI3K/Akt pathway in acute myeloid leukemia may enhance the efficacy of mTOR inhibitors in treatment of this disease |
685788 |
| 2.7.1.137 | medicine |
inhibition of PI 3-K enhances the susceptibility of oral squamous cell carcinoma cells to anticancer drug-mediated apoptosis through regulation of expression and post-translational modification of both pro- and antiapoptotic proteins. These findings could potentially lead to new strategies for improving the efficacy of anticancer drugs in oral squamous cell carcinoma cells |
687179 |
| 2.7.1.137 | medicine |
inhibition of the class I PI3K signaling pathway is a potential strategy for managing gastric cancers |
684123 |
| 2.7.1.137 | medicine |
inhibitors of PI3K/Akt may prove to be useful novel therapies in the treatment of asthma and chronic obstructive pulmonary disease |
688596 |
| 2.7.1.137 | medicine |
p110a is a target for cancer therapies |
677231 |
